Affordable Access

deepdyve-link
Publisher Website

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.

Authors
  • Regueiro, Miguel1
  • Feagan, Brian G2
  • Zou, Bin3
  • Johanns, Jewel3
  • Blank, Marion A4
  • Chevrier, Marc3
  • Plevy, Scott3
  • Popp, John4
  • Cornillie, Freddy J5
  • Lukas, Milan6
  • Danese, Silvio7
  • Gionchetti, Paolo8
  • Hanauer, Stephen B9
  • Reinisch, Walter10
  • Sandborn, William J11
  • Sorrentino, Dario12
  • Rutgeerts, Paul13
  • 1 Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: [email protected]
  • 2 Robarts Research Institute, University of Western Ontario, London, Ontario, Canada. , (Canada)
  • 3 Janssen Research & Development, LLC, Spring House, Pennsylvania.
  • 4 Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
  • 5 MSD International, Luzern, Switzerland. , (Switzerland)
  • 6 Charles University, Prague, Czech Republic. , (Czechia)
  • 7 Istituto Clinico Humanitas, Milan, Italy. , (Italy)
  • 8 S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. , (Italy)
  • 9 Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • 10 McMaster University, Hamilton, Ontario, Canada; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. , (Austria)
  • 11 University of California San Diego, La Jolla, California.
  • 12 Virginia Tech, Carilion School of Medicine, Roanoke, Virginia; Department of Clinical and Experimental Pathology, University of Udine School of Medicine, Udine, Italy. , (Italy)
  • 13 University Hospital Gasthuisberg, Leuven, Belgium. , (Belgium)
Type
Published Article
Journal
Gastroenterology
Publication Date
June 2016
Volume
150
Issue
7
Pages
1568–1578
Identifiers
DOI: 10.1053/j.gastro.2016.02.072
PMID: 26946343
Source
Medline
Keywords
License
Unknown

Abstract

Infliximab is not superior to placebo in preventing clinical recurrence after CD-related resection. However, infliximab does reduce endoscopic recurrence. ClinicalTrials.gov ID NCT01190839.

Report this publication

Statistics

Seen <100 times